WEDNESDAY, June 18, 2025 (HealthDay News) — For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published online June 11 in The Lancet Psychiatry. Leslie Citrome, M.D., from the New York Medical College School of Medicine in Valhalla, and colleagues conducted an open-label, nonrandomized, phase 3 […]
The post Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia first appeared on Physician’s Weekly.
